AGEN.US Agenus Inc

Healthcare Biotechnology USA Stocks
6.87 USD
Close of Nov 13, 2026
2.71 10.31
Market cap
USD 311M
P/E
29.9x
P/B
218.61x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AGEN.US undervalued?

Graham number

The Graham number of Agenus Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Agenus Inc fundamental analysis

No fundamental analysis for Agenus Inc yet.

Agenus Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Agenus Inc

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) b…

Full company profile